Free public records show BrightGene Bio-Medical Technology Co., Ltd. in 4 of the markets we cover. It is not a key player in our research.
[1] ClinicalTrials.gov, Studies led by BrightGene Bio-Medical Technology Co., Ltd. or a part of it that are recruiting, about to start or running. Retrieved 13 Nov 2026.
From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.
7 active studies led by BrightGene Bio-Medical Technology Co., Ltd., of 18 in all
Source: ClinicalTrials.gov, Studies with BrightGene Bio-Medical Technology Co., Ltd. (or a part of it) as lead sponsor; active = recruiting, about to start or running. Retrieved 13 Nov 2026.
Studies BrightGene Bio-Medical Technology Co., Ltd. leads, by the year they started and their phase
Source: ClinicalTrials.gov, Studies with BrightGene Bio-Medical Technology Co., Ltd. or a part of it as lead sponsor, by start year (since 2015) and phase. Retrieved 13 Nov 2026.
Markets we cover where free public records show BrightGene Bio-Medical Technology Co., Ltd.: trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.
The topics of the markets BrightGene Bio-Medical Technology Co., Ltd. is in.
Stories on the topics BrightGene Bio-Medical Technology Co., Ltd. works in.
2.6 billion adults are overweight. GLP-1 medicines are changing weight care, while most supplements lack…
Read
Nearly 15% of US Medicare beneficiaries, 8.2 million people, had a wound or wound infection in one year…
Read
TB killed 1.23 million people in 2024. WHO now recommends rapid molecular tests first, bringing lab-grade…
ReadSearch all reports for BrightGene Bio-Medical Technology Co., Ltd. All companies